CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Kaleido Biosciences Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Kaleido Biosciences Inc
18 Crosby Drive
Phone: (617) 674-9000p:617 674-9000 BEDFORD, MA  01730  United States Ticker: KLDOKLDO
This company ceased filing statements with the SEC on 5/6/2022.
On 4/8/2022, the Company's board of directors voted to end all company operations, which includes the immediate termination of all employees that remained with the company.
Business Summary
Kaleido Biosciences, Inc. is a clinical-stage healthcare company focused on microbiome organs to treat disease and improve human health. The Company’s product candidates are Microbiome Metabolic Therapies (MMTs), which are designed to modulate the metabolic output and profile of the microbiome by driving the function and composition of existing microbes. It is advancing a pipeline of MMT candidates to address a range of diseases and conditions with unmet patient needs. KB109 and KB174 are the MMT candidates for development for the prevention of infections caused by multi-drug resistant (MDR) bacteria. The nomination of these candidates resulted from their performance relative to a range of other MMTs in ex vivo screening of microbiome samples from healthy volunteers as well as microbiome samples from intensive care unit patients in an experimental set-up that specifically focused on determining the potential of MMTs to decrease the relative abundance of a panel of pathogenic bacteria.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-YesYesYes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202112/31/2021YesYes---

Industries
SIC Code Description
2836 Biological products, except diagnostic substances
8731 Commercial physical and biological research
2834 Pharmaceutical preparations

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board TheoMelas-Kyriazi 8/9/2021 7/11/2019
Independent Director Bonnie L.Bassler 59 12/20/2018 12/20/2018
Independent Director Jean K.Mixer 55 9/30/2019 9/30/2019
Independent Director AnnePrener 64 4/1/2020 4/1/2020
Independent Director Anthony G.Quinn 62 2/1/2016 2/1/2016

Business Names
Business Name
Cadena Bio, Inc.
KALEIDO BIOSCIENCES INC
Kaleido Biosciences Securities Corporation
KLDO

General Information
Number of Employees: 76 (As of 12/31/2021)
Outstanding Shares: 42,622,559 (As of 3/31/2022)
Shareholders: 67
Stock Exchange: OTC
Fax Number: (302) 655-5049
Email Address: info@kaleido.com


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, November 16, 2024